Chronic granulomatous disease
What is Chronic granulomatous disease?
Chronic granulomatous disease (CGD) is a rare inherited immunodeficiency disorder that affects the body’s ability to fight certain types of infections. The condition occurs when white blood cells called phagocytes cannot properly destroy bacteria and fungi, leading to recurrent, severe infections and inflammation. CGD affects approximately 1 in 200,000 to 250,000 people worldwide, with symptoms typically appearing in early childhood. While challenging to live with, advances in treatment and supportive care have significantly improved outcomes for people with this condition.
Key statistics
| Prevalence | 1 in 200,000–250,000 births |
| Age of onset | Usually before age 5, often in infancy |
| Male predominance | 65% of cases (X-linked inheritance) |
| Carrier frequency | Approximately 1 in 200 females for X-linked form |
Symptoms
Recurrent infections, pneumonia, abscesses, granulomas, lymphadenopathy, failure to thrive, chronic diarrhea, skin infections, liver complications.
The hallmark of CGD is severe, recurrent infections that begin early in life. Most children develop their first serious infection before age 2. Common early symptoms include persistent skin infections, swollen lymph nodes, and pneumonia that doesn’t respond well to typical antibiotics. Aspergillus fungal infections of the lungs are particularly characteristic of CGD.
Abscesses frequently develop in the liver, lungs, lymph nodes, and skin. These collections of infected material often require surgical drainage and prolonged antibiotic treatment. The formation of granulomas—clusters of inflammatory cells—gives the disease its name and can cause blockages in the gastrointestinal and urinary tracts.
Children with CGD may experience failure to thrive, with poor weight gain and delayed growth. Chronic diarrhea is common, often due to inflammatory bowel disease-like symptoms. The constant battle against infections can lead to fatigue and reduced energy levels.
Causes and risk factors
CGD is caused by mutations in genes that produce components of the NADPH oxidase enzyme complex. This enzyme is crucial for generating reactive oxygen species that white blood cells use to kill bacteria and fungi. When the enzyme doesn’t work properly, certain microorganisms can survive and multiply within immune cells.
The condition follows two inheritance patterns. X-linked CGD, caused by mutations in the CYBB gene, accounts for about 65% of cases and primarily affects males. Autosomal recessive forms, involving mutations in NCF1, NCF2, NCF4, or CYBA genes, affect males and females equally.
The main risk factor is having a family history of CGD or carrying genetic mutations associated with the condition. Consanguinity (parents being related) increases the risk of autosomal recessive forms.
Prevention
As a genetic condition, CGD cannot be prevented through lifestyle modifications. However, genetic counseling and testing play crucial roles in family planning. Carrier testing can identify individuals who carry one copy of a CGD-causing mutation, particularly important for the X-linked form where carrier mothers have a 50% chance of passing the condition to each son.
Prenatal testing is available through amniocentesis or chorionic villus sampling for families with known genetic mutations. Preimplantation genetic diagnosis (PGD) during in vitro fertilization offers another option for preventing transmission.
Once diagnosed, infection prevention becomes paramount through prophylactic medications, vaccinations, and environmental precautions.
Complications
Without proper treatment, CGD leads to life-threatening complications. Severe pneumonia, particularly from Aspergillus fungi, can cause permanent lung damage and respiratory failure. Liver abscesses may require multiple surgical procedures and can lead to liver dysfunction.
Gastrointestinal complications include inflammatory bowel disease-like symptoms, intestinal obstruction from granulomas, and malnutrition. Genitourinary tract involvement can cause kidney infections and urinary blockages.
The chronic inflammatory response can affect growth and development in children. Some patients develop autoimmune conditions, including discoid lupus and other inflammatory disorders. Without treatment, CGD historically had a poor prognosis, with many patients not surviving childhood.
Diagnosis
The diagnostic journey for CGD often begins with recognizing a pattern of unusual, recurrent infections. The dihydrorhodamine (DHR) flow cytometry test is the primary screening tool, measuring the ability of neutrophils to produce reactive oxygen species. In CGD, this test shows significantly reduced or absent activity.
Additional laboratory tests include the nitroblue tetrazolium (NBT) test, which provides similar information but is less sensitive than DHR. Genetic testing confirms the diagnosis and identifies the specific gene mutation, which is important for inheritance counseling and treatment planning.
Imaging studies may reveal characteristic findings such as pulmonary infiltrates, liver abscesses, or lymphadenopathy. Tissue biopsies sometimes show the characteristic granulomatous inflammation, though this is not always necessary for diagnosis.
Immunological workup includes assessment of other immune functions to rule out additional immunodeficiencies. Family history and genetic counseling are essential components of the diagnostic process.
Treatment
Treatment focuses on preventing and managing infections while supporting overall health. Prophylactic antibiotics, typically trimethoprim-sulfamethoxazole, are used daily to prevent bacterial infections. Antifungal prophylaxis with itraconazole helps prevent Aspergillus infections.
Interferon gamma-1b is an approved immunomodulatory therapy that enhances the function of remaining immune cells and reduces infection frequency. This treatment requires regular subcutaneous injections but has shown significant benefits in clinical trials.
When infections occur, aggressive treatment with appropriate antimicrobials is essential. Fungal infections often require prolonged courses of antifungal medications such as voriconazole or amphotericin B.
Hematopoietic stem cell transplantation (HSCT) offers the potential for cure, particularly in severe cases or when complications become life-threatening. Gene therapy is emerging as a promising treatment option, with early clinical trials showing encouraging results.
Prognosis
The prognosis for CGD has improved dramatically with modern treatment approaches. With proper prophylactic care and prompt treatment of infections, many patients now survive well into adulthood. Life expectancy has increased from a median of 12 years historically to potentially normal lifespans with optimal care.
Factors affecting prognosis include the specific genetic subtype, age at diagnosis, access to specialized care, and adherence to prophylactic treatments. The X-linked form tends to be more severe than autosomal recessive variants. Early diagnosis and treatment initiation are crucial for preventing serious complications.
Quality of life can be good with proper management, though the condition requires lifelong vigilance and medical care. Successful stem cell transplantation can result in cure, with normal immune function restoration.
Quality of life
Living with CGD requires careful attention to infection prevention while maintaining as normal a life as possible. Daily prophylactic medications become routine, and regular medical monitoring is essential. Patients and families learn to recognize early signs of infection and seek prompt medical attention.
Environmental precautions include avoiding certain high-risk exposures such as construction sites, compost, and moldy environments where Aspergillus exposure is likely. Swimming in natural bodies of water may be restricted due to infection risks.
Nutrition plays an important role, with attention to maintaining good overall health and supporting immune function. Regular exercise is encouraged within safe parameters. Mental health support is valuable for both patients and families dealing with the stress of chronic illness.
Educational accommodations may be needed during periods of illness or hospitalization. Many adults with CGD work successfully in careers that don’t involve high infection risks.
Pregnancy and fertility
CGD typically doesn’t directly affect fertility in either men or women. However, pregnancy requires careful management in affected women, with attention to infection prevention and medication safety. Some prophylactic medications may need adjustment during pregnancy and breastfeeding.
Genetic counseling is crucial for family planning. Women with CGD have varying risks of passing the condition to children depending on their genetic subtype. Prenatal testing options should be discussed with genetic counselors and maternal-fetal medicine specialists.
Partners of individuals with CGD may benefit from carrier testing, particularly for autosomal recessive forms where both parents must be carriers for children to be affected.
Children
CGD typically manifests in early childhood, making pediatric care essential. Children require age-appropriate medication formulations and dosing. Growth and development monitoring is important, as chronic illness can affect normal progression.
School attendance may be interrupted by infections or medical appointments. Educational teams should be informed about the condition and emergency protocols. Immunization schedules require modification, with live vaccines generally contraindicated.
Social and emotional support helps children cope with having a chronic condition. Connecting with other families affected by CGD through patient organizations can provide valuable peer support.
When to see a doctor
Immediate medical attention is needed for fever, signs of pneumonia (cough, difficulty breathing), or symptoms suggesting abscess formation (localized pain, swelling, warmth). Any infection that doesn’t respond to initial treatment requires prompt evaluation.
Routine care includes regular follow-up with immunology specialists, monitoring for medication side effects, and preventive health measures. Annual assessments typically include imaging studies to check for occult infections.
Emergency situations include severe breathing difficulties, high fever with signs of sepsis, or any rapidly progressing infection. Families should have clear action plans for accessing specialized care when needed.
Regional context
Limited specific data exists regarding CGD prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries. The condition’s rarity makes regional epidemiological studies challenging. Consanguinity rates in some populations may affect the frequency of autosomal recessive forms.
Healthcare infrastructure for managing rare immunodeficiencies varies across the region. Access to specialized testing, prophylactic medications, and stem cell transplantation may be limited in some areas.
The Global Medical Journal welcomes contributions from healthcare professionals in these regions to better understand CGD presentation and management challenges in diverse populations.
Research and clinical trials
Gene therapy represents one of the most promising research directions for CGD. Recent clinical trials have shown successful correction of the genetic defect in some patients, offering hope for curative treatment without the risks associated with stem cell transplantation.
Improved conditioning regimens for stem cell transplantation are being studied to reduce toxicity while maintaining effectiveness. Novel prophylactic approaches and immunomodulatory treatments are also under investigation.
Research into biomarkers that predict infection risk or treatment response could help personalize care. Studies of the inflammatory complications of CGD may lead to targeted anti-inflammatory therapies.
Patients and families can find information about current clinical trials at ClinicalTrials.gov, though specialized immunodeficiency centers provide the best guidance about trial eligibility and potential benefits.
Frequently asked questions
Can people with CGD live normal lifespans?
With proper treatment and prophylactic care, many people with CGD now live well into adulthood with good quality of life. Early diagnosis and adherence to treatment protocols are key factors in achieving optimal outcomes.
Is CGD contagious?
No, CGD is not contagious. It’s a genetic condition affecting the immune system’s ability to fight certain infections. People with CGD are at risk of getting infections from environmental sources, but they cannot transmit CGD to others.
What infections are most dangerous for CGD patients?
Aspergillus fungal infections and certain bacteria like Staphylococcus aureus, Burkholderia, and Nocardia species pose the greatest risks. These organisms are particularly resistant to the impaired immune responses in CGD patients.
Can CGD be cured?
Stem cell transplantation can cure CGD by replacing the defective immune system with healthy donor cells. Gene therapy is also showing promise as a potential cure. However, these treatments carry risks and aren’t appropriate for all patients.
How is CGD inherited?
CGD can be inherited in X-linked or autosomal recessive patterns. X-linked CGD primarily affects males and is passed from carrier mothers. Autosomal recessive CGD affects both sexes equally and requires both parents to be carriers.
Support and resources
- CGD Association – Primary patient advocacy organization providing support, education, and research funding
- Orphanet – European database of rare diseases and orphan drugs
- National Organization for Rare Disorders (NORD) – US-based rare disease advocacy and support
- EURORDIS – European umbrella organization for rare disease patient groups
- Immune Deficiency Foundation – Support and education for primary immunodeficiency diseases
- World Health Organization (WHO) – Global health information and resources
Related conditions
- Severe Combined Immunodeficiency (SCID)
- Wiskott-Aldrich Syndrome
- Hyper-IgE Syndrome
- Leukocyte Adhesion Deficiency
- Severe Congenital Neutropenia
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Chronic granulomatous disease.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/chronic-granulomatous-disease/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?